TY  - JOUR
AU  - Erazo, Tatiana 
AU  - Lorente Pérez, María Del Mar
AU  - Lopez-Plana, Anna 
AU  - Munoz-Guardiola, Pau
AU  - Fernandez-Nogueira, Patricia
AU  - García-Martínez, Jose
AU  - Bragado Domingo, Paloma
AU  - Fuster, Gemma 
AU  - Salazar Roa, María
AU  - Espadaler, Jordi 
AU  - Hernandez-Losa, Javier 
AU  - Bayascas, Jose Ramon 
AU  - Cortal, Marc 
AU  - Vidal, Laura 
AU  - Gascon, Pedro 
AU  - Gomez-Ferreria, Mariana 
AU  - Alfon, Jose 
AU  - Velasco Díez, Guillermo
AU  - Domenech, Carles 
AU  - Lizcano, Jose 
PY  - 2016
DO  - 10.1158/1078-0432.CCR-15-1808
SN  - 1078-0432
UR  - https://hdl.handle.net/20.500.14352/97280
T2  - Clinical Cancer Research
AB  - Purpose: ABTL0812 is a novel first-in-class, small molecule which showed antiproliferative effect on tumor cells in phenotypic assays. Here we describe the mechanism of action of this antitumor drug, which is currently in clinical...
LA  - eng
M2  - 2508
PB  - American Association for Cancer Research
KW  - ABTL0812
KW  - AKT/mTOR axis
KW  - Cancer
TI  - The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
TY  - journal article
VL  - 22
ER  -